From the weekly letter · 9 November 2026

Why cover this story this week?

A molecular warning before prion symptoms

For people carrying an inherited prion-disease mutation, a test of cerebrospinal fluid may help distinguish genetic risk from an approaching clinical transition. Researchers analysed longitudinal samples from 94 PRNP E200K mutation carriers using RT-QuIC, an assay that detects the ability of abnormal prion protein to seed amyloid formation. Eleven carriers developed disease, and all had tested positive before symptoms. First positivity appeared a median of 2.0 years before onset.

Carriers who remained asymptomatic stayed negative throughout follow-up, while a positive result marked substantially higher short-term conversion risk. This clinical preprint offers a potential way to select and monitor participants in preventive studies: intervening before symptoms requires knowing when disease biology is becoming active. It does not yet establish a universal countdown to onset; the reported interval varied, and the evidence concerns this mutation.

Editorial context written by AI from abstracts, not independent scientific validation. The kit and its verified quotes rely on the source paper, not on this letter.

Read the full letter →

Talk about a paper in public without overstating it: yours, one you are asked to comment on, or one you write about as a journalist.

  • Your paper: a draft release for your press office, the questions journalists will ask with what the paper lets you answer, the likely misreadings, a lay summary and a short thread.
  • Asked to comment: what the paper shows and does not, its strengths and weaknesses with their passages, and what would settle its main claim.
  • Writing about it as a journalist: reporting angles, the wording to check before publication, and the questions to ask the authors.
  • For everyone: findings with their passages checked word for word, the novelty set against the closest earlier papers, a hype check, figures with their credit, and researchers for an outside view who have not signed with the authors.

Discover Premium+ See an example kit